[{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Funding","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"MediWound \/ EIC Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ EIC Accelerator"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Molnlycke Health Care","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Private Placement","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ Molnlycke Health Care","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Molnlycke Health Care"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Amiodarone Hydrochloride","moa":"HERG","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Escharex","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Escharex","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Escharex","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Mesenchymal-Like Adherent Stromal Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Mesenchymal-Like Adherent Stromal Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Niacin","moa":"VLDL\/LDL synthesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kitov Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kitov Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kitov Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kitov Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2025","type":"Public Offering","leadProduct":"EscharEx","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ H.C. Wainwright & Co"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
